The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
|Videos|July 30, 2019
Heavily Pretreated Recurrent Ovarian Cancer
Heavily Pretreated Recurrent Ovarian Cancer
Advertisement
Case: A 58-Year-Old Female With Heavily Pretreated Recurrent Ovarian Cancer
H & P
- 58-year-old female diagnosed in 2014 with stage IV ovarian cancer
- Pathology: high-grade serous carcinoma, epithelial ovarian cancer
- CA-125: 460 U/mL
- CT with contrast of the pelvis, abdomen, and chest revealed a 4-cm mass in the left ovary and peritoneal carcinomatosis
- Patient underwent suboptimal debulking surgery; residual disease 1.5 cm
- Received IV/IP carboplatin/paclitaxel (6 cycles); achieved complete remission
- 2 years later (2016) symptoms returned; CA 125, 255 U/mL; ECOG: 1
- Received carboplatin/paclitaxel (6 cycles) and bevacizumab; achieved good partial remission; CA 125, 45 U/mL; continued on bevacizumab maintenance
- 1.5-years following second-line therapy (2017), again presented with symptoms; CA 125, 550 U/mL; ECOG: 0
- Genetic testing;gBRCA1/2wild-type
- Received carboplatin/gemcitabine (6 cycles); CA 125, 46 U/mL; achieved complete remission
- Currently:
- CA 125, 620 U/mL
- CT shows several small masses in the lung left lower lobe (largest is 3 cm)
- ECOG: 0
Advertisement
Related to this article
Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
September brought accelerated approvals in ESR1-mutant breast cancer and HER2-mutant non–small cell lung cancer, a Galleri panel vote, and a withdrawn I-DXd application.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5